<VariationArchive VariationID="463017" VariationName="NM_003482.4(KMT2D):c.4812dup (p.Met1605fs)" VariationType="Duplication" Accession="VCV000463017" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2017-12-26" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="462216" VariationID="463017">
      <GeneList>
        <Gene Symbol="KMT2D" FullName="lysine methyltransferase 2D" GeneID="8085" HGNC_ID="HGNC:7133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.12</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="49018978" stop="49060794" display_start="49018978" display_stop="49060794" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="49412757" stop="49449106" display_start="49412757" display_stop="49449106" Strand="-" />
          </Location>
          <OMIM>602113</OMIM>
          <Haploinsufficiency last_evaluated="2020-01-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KMT2D">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-01-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KMT2D">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_003482.4(KMT2D):c.4812dup (p.Met1605fs)</Name>
      <CanonicalSPDI>NC_000012.12:49044894:GG:GGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q13.12</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="49044894" stop="49044895" display_start="49044894" display_stop="49044895" variantLength="1" positionVCF="49044894" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="49438677" stop="49438678" display_start="49438677" display_stop="49438678" variantLength="1" positionVCF="49438677" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
      </Location>
      <ProteinChange>M1605fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.49438679dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.49438679dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.49044896dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.49044896dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_027827.1" sequenceAccession="NG_027827" sequenceVersion="1" change="g.15430dup">
            <Expression>NG_027827.1:g.15430dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003482.4" sequenceAccession="NM_003482" sequenceVersion="4" change="c.4812dup" MANESelect="true">
            <Expression>NM_003482.4:c.4812dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003473.3" sequenceAccession="NP_003473" sequenceVersion="3" change="p.Met1605fs">
            <Expression>NP_003473.3:p.Met1605fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003482.3" sequenceAccession="NM_003482" sequenceVersion="3" change="c.4812dupC">
            <Expression>NM_003482.3:c.4812dupC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA658658146" DB="ClinGen" />
        <XRef Type="rs" ID="1555194510" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003482.4(KMT2D):c.4812dup (p.Met1605fs) AND Kabuki syndrome" Accession="RCV000547428" Version="5">
        <ClassifiedConditionList TraitSetID="21571">
          <ClassifiedCondition DB="MedGen" ID="C0796004">Kabuki syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-01-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2017-01-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-12-26" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="21571" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="33104" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Niikawa-Kuroki syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kabuki make-up syndrome</ElementValue>
                <XRef ID="Kabuki+syndrome/3945" DB="Genetic Alliance" />
                <XRef ID="313426007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Kabuki syndrome</ElementValue>
                <XRef ID="MONDO:0016512" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS147920" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NKS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">KMS</ElementValue>
                <XRef Type="MIM" ID="147920" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects, genitourinary anomalies, cleft lip and/or palate, gastrointestinal anomalies including anal atresia, ptosis and strabismus, and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.</Attribute>
                <XRef ID="NBK62111" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6810" />
                <XRef ID="6810" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">21882399</ID>
                <ID Source="BookShelf">NBK62111</ID>
              </Citation>
              <XRef ID="2322" DB="Orphanet" />
              <XRef ID="C0796004" DB="MedGen" />
              <XRef ID="MONDO:0016512" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS147920" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1229162" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1419243|MedGen:C0796004" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000636662" DateUpdated="2024-02-28" DateCreated="2017-12-26" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-01-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>For these reasons, this variant has been classified as Pathogenic. While this particular variant has not been reported in the literature, loss-of-function variants in KMT2D are known to be pathogenic (PMID:¬†24633898, 22126750). This sequence change inserts 1 nucleotide in exon 19 of the KMT2D mRNA (c.4812dupC), causing a frameshift at codon 1605. This creates a premature translational stop signal (p.Met1605Hisfs*26) and is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KMT2D" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.49438677_49438678insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0796004" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB3109251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1229162" TraitType="Disease" MappingType="XRef" MappingValue="C0796004" MappingRef="MedGen">
        <MedGen CUI="C0796004" Name="Kabuki syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

